Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study

Table 2 Progression Free Survival (PFS) analysis by Cox regression results

Factor	HR	95% CI	p-value
miRNA-22 (above vs. below median value)	5.19	1.38–19.56	0.015
IPI
Intermediate vs. low	1.03	0.19–5.62	0.977
High vs. intermediate-low	2.07	0.67–6.48	0.209
Cell of origin (non-GC vs. GC)	0.42	0.13–1.38	0.153
Double hit (yes vs. no) (^)	2.88	0.78–10.72	0.113

HR: hazard ratio; CI: confidence intervals; IPI: International Prognostic Index;
GC: germinal-center; non-GC: non germinal center
(^) Datum not available for all patients (see methods)

ISSN: 1756-9966